VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

MVA expressing HIV Gag, Pol and Env proteins
Vaccine Information
  • Vaccine Name: MVA expressing HIV Gag, Pol and Env proteins
  • Target Pathogen: Human Immunodeficiency Virus
  • Target Disease: Acquired Immunodeficiency Syndrome (AIDS)
  • Vaccine Ontology ID: VO_0000824
  • Type: Recombinant vector vaccine
  • Antigen: HIV Gag, Pol, and Env proteins (Liu et al., 2006)
  • Preparation: An rMVA vaccine that expresses HIV Gag, Pol, and Env proteins was constructed (Liu et al., 2006).
Host Response

Mouse Response

  • Host Strain: BALB/c
  • Vaccination Protocol: Female BALB/c mice were used for immunizations. All were conducted on anesthetized mice. Immunizations with MVAs were accomplished by inoculating the desired amount of MVA into a single quadriceps muscle. Immunizations with DNA were accomplished by injecting the desired amount of DNA into the quadriceps, half in each leg (Liu et al., 2006).
  • Persistence: Temporal CD8 responses were conducted in BALB/c mice using MVA. Responses were steady for >10 weeks (>6 weeks post-MVA) (Liu et al., 2006).
  • Immune Response: CD8 T cells were boosted more effectively than CD4 T cells with the ratio of elicited CD8 to CD4 cells for the immunodominant CD8 epitope in Gag increasing with boosts. The most effective boost for CD8 T cells resulted in the greatest skewing of the CD8 to CD4 T cell ratio. This could represent better access of CD8 than CD4 T cells to APCs (Liu et al., 2006). The dose–response studies showed good increases for antigen expression with increasing MVA dose. A 1000-fold increase in the dose of MVA resulted in a 300-fold increase in the frequency of antigen-expressing cells. In contrast, dose–response studies for in vivo immunogenicity showed <10-fold increases in elicited T cells and Ab for 100–1000-fold increases in the dose of inoculated MVA. Shallow dose–response curves for immunogenicity were observed post priming as well as post boosting of an MVA or a DNA prime (Liu et al., 2006).
  • Side Effects: No adverse effects were encountered (Liu et al., 2006).
References
Liu et al., 2006: Liu J, Wyatt LS, Amara RR, Moss B, Robinson HL. Studies on in vitro expression and in vivo immunogenicity of a recombinant MVA HIV vaccine. Vaccine. 2006 Apr 12; 24(16); 3332-9. [PubMed: 16472543].